Guy Goodwin

Guy M. Goodwin is a senior British psychiatrist and academic with a longstanding research career in affective disorders, psychopharmacology and clinical trials. Historically recognised for work on mood disorders and bipolar depression, he has in recent years been a prominent clinical investigator and co‑author on multiple studies examining therapeutic applications of psilocybin — including single‑dose treatment for treatment‑resistant major depressive episodes, long‑term observational follow‑up after psilocybin treatment, and safety and tolerability investigations in post‑traumatic stress disorder. He has also contributed to work on psychological support models for COMP360 psilocybin therapy and to novel analytic approaches such as using natural language processing to predict clinical outcomes.

Goodwin’s contributions bridge traditional psychiatric therapeutics and emerging psychedelic‑assisted therapies: he participates in multidisciplinary trials, authors methodological guidance for psychedelic research, and collaborates with leading groups in the field (including colleagues such as Robin Carhart‑Harris and Scott T. Aaronson). His emphasis remains on rigorous safety evaluation, clinical outcome measurement and integration of psychopharmacological knowledge into the design and interpretation of psychedelic therapy studies.